Congress Park Capital
CTMX icon

Congress Park Capital’s CytomX Therapeutics CTMX Stock Holding History

Congress Park Capital’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$73.9K Sell
27,171
-22,000
-45% -$73.4K 0.02% 130
2026
Q2 		$184K Hold
49,171
– – 0.05% 134
2026
Q1 		$231K Sell
49,171
-9,751
-17% -$49.5K 0.07% 121
2025
Q4 		$251K Sell
58,922
-45,000
-43% -$171K 0.07% 112
2025
Q3 		$332K Buy
103,922
+8,500
+9% +$19.1K 0.1% 93
2025
Q2 		$217K Sell
95,422
-578,264
-86% -$932K 0.07% 106
2025
Q1 		$428K Sell
673,686
-290,904
-30% -$226K 0.16% 84
2024
Q4 		$994K Sell
964,590
-251,418
-21% -$270K 0.36% 59
2024
Q3 		$1.43M Buy
1,216,008
+62,788
+5% +$79.8K 0.53% 44
2024
Q2 		$1.41M Buy
1,153,220
+919,420
+393% +$1.83M 0.57% 46
2024
Q1 		$510K Sell
233,800
-5,500
-2% -$10.2K 0.23% 78
2023
Q4 		$371K Buy
239,300
+126,850
+113% +$167K 0.18% 88
2023
Q3 		$145K Buy
112,450
+6,300
+6% +$9.9K 0.08% 113
2023
Q2 		$183K Buy
106,150
+5,950
+6% +$9.9K 0.09% 126
2023
Q1 		$151K Buy
+100,200
New +$226K 0.08% 130
2021
Q2 		– Sell
-20,207
Closed -$156K – 142
2021
Q1 		$156K Sell
20,207
-5,600
-22% -$44.3K 0.09% 125
2020
Q4 		$169K Sell
25,807
-52,754
-67% -$377K 0.1% 110
2020
Q3 		$522K Sell
78,561
-7,750
-9% -$57.5K 0.32% 59
2020
Q2 		$719K Sell
86,311
-12,300
-12% -$114K 0.55% 43
2020
Q1 		$756K Buy
98,611
+3,950
+4% +$27.5K 0.68% 35
2019
Q4 		$787K Sell
94,661
-73,150
-44% -$494K 0.58% 39
2019
Q3 		$1.24M Sell
167,811
-800
-0.5% -$7.89K 1.04% 28
2019
Q2 		$1.72M Sell
168,611
-42,895
-20% -$450K 1.36% 24
2019
Q1 		$2.27M Buy
211,506
+88,195
+72% +$1.3M 1.97% 16
2018
Q4 		$1.86M Buy
123,311
+11,125
+10% +$165K 2.05% 15
2018
Q3 		$2.08M Buy
112,186
+2,661
+2% +$60.6K 1.86% 15
2018
Q2 		$2.5M Buy
109,525
+1,800
+2% +$46K 2.4% 10
2018
Q1 		$3.06M Sell
107,725
-18,250
-14% -$521K 3.15% 6
2017
Q4 		$2.66M Buy
+125,975
New +$2.61M 2.68% 7

Other funds holding CTMX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Peak Financial Advisors
Peak Financial Advisors Denver, Colorado $232M AUM 12.16% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Robertson Stephens Wealth Management
Robertson Stephens Wealth Management San Francisco, California $4.14B AUM 13.63% 1-Year Est. Return
NLB Skladi upravljanje premozenja
NLB Skladi upravljanje premozenja Ljubljana $2.71B AUM 53.8% 1-Year Est. Return
Miller Financial Services
Miller Financial Services Marshall, Michigan $132M AUM 10.64% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Congress Park Capital's CTMX Position: Q3 2026 in Review

Congress Park Capital reduced its CytomX Therapeutics (CTMX) stake by 45% in Q3 2026, selling an estimated $73.4K and leaving 27,171 shares worth $73.9K. The position accounts for 0.02% of the portfolio, ranked #130.

Congress Park Capital first reported a position in CTMX in Q4 2017 and has held it in 29 quarters since. The position peaked at $3.06M in Q1 2018. 28 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.

  • Congress Park Capital held 27,171 shares of CytomX Therapeutics worth $73.9K as of Q3 2026.
  • Congress Park Capital sold 22,000 CytomX Therapeutics shares in Q3 2026, an estimated $73.4K.
  • CytomX Therapeutics made up 0.02% of Congress Park Capital's portfolio in Q3 2026, its #130 holding.
  • Congress Park Capital first reported a position in CytomX Therapeutics in Q4 2017 and has held it in 29 quarters since.
  • Congress Park Capital's CytomX Therapeutics position peaked at $3.06M in Q1 2018.
  • 28 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.

Based on Congress Park Capital's 13F filing for Q3 2026, filed 13 Oct 2026.